Incyte (BSP:I1NC34) Net Margin %

: 19.84% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. Incyte's Net Income for the three months ended in Dec. 2023 was R$985 Mil. Incyte's Revenue for the three months ended in Dec. 2023 was R$4,965 Mil. Therefore, Incyte's net margin for the quarter that ended in Dec. 2023 was 19.84%.

The historical rank and industry rank for Incyte's Net Margin % or its related term are showing as below:

BSP:I1NC34' s Net Margin % Range Over the Past 10 Years
Min: -20.38 Med: 7.63 Max: 31.76
Current: 16.17

BSP:I1NC34's Net Margin % is ranked better than
87.62% of 1026 companies
in the Biotechnology industry
Industry Median: -163.08 vs BSP:I1NC34: 16.17

Incyte Net Margin % Historical Data

The historical data trend for Incyte's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

20.70

-11.09

31.76

10.04

16.17

Incyte Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %																3.07	2.68	21.32	18.64	19.84

Competitive Comparison

For the Biotechnology subindustry, Incyte's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Incyte Net Margin % Distribution

For the Biotechnology industry and Healthcare sector, Incyte's Net Margin % distribution charts can be found below:

* The bar in red indicates where Incyte's Net Margin % falls into.

Incyte Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Incyte's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	2928.116	/	18107.941
	=	16.17 %

Incyte's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	985.247	/	4965.168
	=	19.84 %

Incyte (BSP:I1NC34) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Incyte Net Margin % Related Terms

Thank you for viewing the detailed overview of Incyte's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Incyte (BSP:I1NC34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (BSP:I1NC34) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

INCY:USA 1INCY:Italy ICY:Germany

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Incyte (BSP:I1NC34) Headlines

No Headlines